The effect of alendronate sodium on spinal fusion: A rabbit model

Spine Journal

Volumn 4, Issue 1, 2004, Pages 36-43

  Lehman Jr , Ronald A ^a,d   Kuklo, Timothy R ^a   Freedman, Brett A ^a   Cowart, Jerry R ^b   Mense, Mark G ^b   Riew, K Daniel ^c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Alendronate sodium; Model; Osteoporosis; Posterolateral fusion; Pseudarthrosis; Rabbit

Indexed keywords

ALENDRONIC ACID; PLACEBO; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRODESIS; ARTICLE; BONE GRAFT; CELL ACTIVITY; CLINICAL EXAMINATION; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG WITHDRAWAL; EXPERIMENTAL MODEL; FRACTURE HEALING; HISTOPATHOLOGY; ILIAC CREST; INHIBITION KINETICS; LUMBAR SPINE; LUMBAR VERTEBRA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PALPATION; POSTOPERATIVE PERIOD; QUALITY CONTROL; RABBIT; SCORING SYSTEM; SPINE FUSION; SPINE MOBILITY; SPINE RADIOGRAPHY; SURVIVAL;

ADMINISTRATION, ORAL; ALENDRONATE; ANIMALS; AWARDS AND PRIZES; DISEASE MODELS, ANIMAL; LUMBAR VERTEBRAE; ORTHOPEDICS; OSTEOGENESIS; RABBITS; RANDOM ALLOCATION; SPINAL FUSION; UNITED STATES; WOUND HEALING;

EID: 0347765809     PISSN: 15299430     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1529-9430(03)00427-3     Document Type: Article

References (45)

1. Boden S.D. The biology of posterolateral lumbar spine fusion Ortho Clin North Am 29 1998 603-619
2. Depalma A.F. Rothman R.H. The nature of pseudarthrosis Clin Orthop 59 1968 113-118
3. Steinmann J.C. Herkowitz H.N. Pseudarthrosis of the spine Clin Orthop 284 1992 80-90
4. Boden S.D. Schimandle J.H. Hutton W.C. An experimental lumbar intertransverse process spinal fusion model Spine 20 1995 412-420
5. Long J. Lewis S. Kuklo T.R. et al. The effect of cyclooxygenase-2 inhibitors on spinal fusion Spine 84 2002 1763-1768
6. Curylo L.J. Johnstone B. Petersilge C.A. et al. Augmentation of spinal arthrodesis with autologous bone marrow in a rabbit posterolateral spine fusion model Spine 24 1999 434-439
7. Sato M. Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy J Bone Miner Res 5 1990 31-40
8. Sato M. Grasser W. Endo N. et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure J Clin Invest 88 1991 2095-2105
9. Fisher J.E. Rogers M.J. Halasy J.M. et al. Alendronate mechanism of action: geranylgeraniol, and intermediate in the mevalonate pathway, prevents inhibition of osteoclast function, bone resorption, and kinase activation in vitro Proc Natl Acad Sci USA 96 1999 133-138
10. Khan S.A. Kanis J.A. Vasikaran S. et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis J Bone Miner Res 12 1997 1700-1707
11. Erulkar J.S. Grauer J.N. Patel T.C. et al. Flexibility analysis of posterolateral fusions in a New Zealand white rabbit model Spine 26 2001 1125-1130
12. Vasikaran S.D. Bisphosphonates: an overview with special reference to alendronate Ann Clin Biochem 38 2001 608-623
13. Halasy-Nagy J.M. Rodan G.A. Reszka A.A. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis Bone 29 2001 553-559
14. Fisher J.E. Rodan G.A. Reszka A.A. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway Endocrinology 141 2000 4793-4796
15. Tsuchimoto M. Azuma Y. Higuchi O. et al. Alendronate modulates osteogenesis of human ostoblastic cells in vitro Jpn J Pharmacol 66 1994 25-33
16. Liberman U.A. Weiss S.R. Broll J. et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis N Engl J Med 333 1995 1437-1443
17. Pols H.A.P. Felsenberg D. Hanley D.A. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study Osteoporosis Int 9 1999 461
18. Chesnut C.H. McClung M.R. Ensrud K.E. et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling Am J Med 99 1995 144-152
19. Black D.M. Cummings S.R. Karpf D.B. et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1996 1535-1541
20. Karpf D.B. Shapiro D.R. Seeman E. et al. Prevention of nonvertebral fractures by alendronate: a meta-analysis JAMA 277 1997 1159-1164
21. Povoroznjuk V.V. Bayandina E.I. Nikonenko P.I. et al. Alendronate treatment of the postmenopausal osteoporotic woman with vertebral fractures Bone 22 1998 B68
22. Shapiro D.R. Thompson D.E. Karpf D.B. et al. Non-vertebral fracture incidence in patients treated with alendronate J Bone Miner Res 10 1995 A150
23. Emery S.E. Brazinski M.S. Koka A. The biological and biomechanical effects of irradiation on anterior spinal bone grafts: a canine model J Bone Joint Surg 76 1994 540-548
24. Bae H, Yee A, Friess D, et al. Alendronate influences bone volume in rabbit posterolateral spine fusion. Paper presented at the 17th Annual North American Spine Society Meeting; October 30-November 2, 2002; Montreal, Quebec, Canada.
25. Osteoporosis prevention, diagnosis, and therapy. National Institutes of Health Consensus Statement, March 27-29, 2000;17(1).
26. Melton L.J. Chrischilles E.A. Cooper C. Perspective. How many women have osteoporosis? J Bone Miner Res 7 1992 1005-1010
27. Miller P.D. Osteoporosis In: Rakel B.A. editor Conn's current therapy 54th ed 2002 586-598 WB Saunders Company Philadelphia
28. Cummings S.R. Black D. Barret-Conner E. et al. Alendronate and fracture prevention JAMA 282 1999 324-325
29. Adami S. Salvagno G. Guarrera et al. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate Calcif Tissue Int 39 1986 226-229
30. Cummings S.R. Black D.M. Thompson D.E. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 1998 2077-2082
31. Ettinger B. Pressman A. Schein J. et al. Alendronate use among 812 women: prevalance of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation J Managed Care Pharm 4 1998 488-492
32. Bauer D.C. Black D. Ensrud K. et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial Arch Intern Med 160 2000 517-525
33. Lenehan T.M. Balligand M. Nunamker D.M. et al. Effect of EHDP on fracture healing in dogs J Orthop Res 3 1985 499-507
34. Mashiba T. Hirano T. Turner C.H. et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces come biomechanical properties in dog rib J Bone Miner Res 15 2000 613-620
35. Flora L. Hassing G.S. Cloyd G.G. et al. The long term skeletal effects of EHDP in dogs Metab Bone Dis Relat Res 3 1981 289-300
36. Chavassieux P.M. Arlot M.E. Reda C. et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis J Clin Invest 100 1997 1475-1480
37. Balena R. Markatos A. Seedor J.G. et al. Long term safety of the aminobisphosphonate alendronate in adult dogs. Histomorphometric analysis of the L5 vertebra J Pharmacol Exp Ther 276 1996 277-283
38. Motoie H. Nakamura T. O'chi N. et al. Effects of bisphosphonate YM175 on bone mineral density, strength, structure and turnover in ovariectomized beagle dogs on concomitant dietary calcium restriction J Bone Miner Res 10 1995 910-920
39. Flora L. Hassing G.S. Parfitt A.M. et al. Comparative skeletal effects of two diphosphonates in dogs Metab Bone Dis Relat Res 2 suppl 1980 389-407
40. Gibbs A.D. D'souza S.M. Ebetino F.H. et al. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate Br Med J 292 1986 1227-1229
41. Steiniche T. Hasling C. Charles P. et al. The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoprosis. A randomized study comparing intermittent treatment and an ADFR regime Bone 12 1991 155-163
42. Storm T. Sriniche T. Thamsborg C. et al. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis J Bone Miner Res 8 1993 199-208
43. Balena R. Toolan B.C. Shea M. et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates J Clin Invest 92 1993 2577-2586
44. Meraw S.J. Reeve C.M. Qualitative analysis of peripheral peri-implant bone and imfluence of alendronate sodium on early bone regeneration J Periodontol 70 1999 1228-1233
45. Meraw S.J. Reeve C.M. Wollan P.C. Use of alendronate in peri-implant defect regeneration J Periodontol 70 1999 151-158